Anti-viral Therapeutics Market - 2021-2031
The Anti-viral Therapeutics Market was valued at US$ 51.72 billion in 2021 and is anticipated to reach US$ 70.83 billion by 2031, at a CAGR of 0.046 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti-viral Therapeutics Market.
This report delivers a comprehensive overview of the Anti-viral Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-viral Therapeutics Market. The Anti-viral Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
Anti-viral Therapeutics Market Scope:
By Mechanism of Action
This report delivers a comprehensive overview of the Anti-viral Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-viral Therapeutics Market. The Anti-viral Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti-viral Therapeutics Market.
This report delivers a comprehensive overview of the Anti-viral Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-viral Therapeutics Market. The Anti-viral Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
Anti-viral Therapeutics Market Scope:
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
- HIV
- Hepatitis
- Herpes Simplex Virus
- Influenza
- Others
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AbbVie Inc.
- Abbott Laboratories
- AstraZeneca plc.
- Pfizer Inc.
- Cipla Inc.(LIST NOT EXHAUSTIVE)
This report delivers a comprehensive overview of the Anti-viral Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-viral Therapeutics Market. The Anti-viral Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market impacting factors
4.2. Drivers
4.2.1. Growing Prevalence of Target Diseases
4.2.2. Strong Pipeline for Antiviral Drugs
4.3. Restraints
4.3.1. High Cost of Deployment
4.3.2. High Cost of Antiviral Drug Treatment
4.4. Opportunity
4.5. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Patent analysis
6. BY MECHANISM OF ACTION
6.1. Introduction
6.1.1. Market size analysis, and y-o-y growth analysis (%), By Mechanism of Action segment
6.1.2. Market attractiveness index, By Mechanism of Action segment
6.2. Nucleotide Polymerase Inhibitors
6.2.1. Introduction
6.2.2. Market size analysis, and y-o-y growth analysis (%)
6.3. Reverse Transcriptase Inhibitors
6.4. Protease Inhibitors
6.5. Others
7. BY APPLICATION
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%), By Application segment
7.1.2. Market attractiveness index, By Application segment
7.2. HIV
7.2.1. Introduction
7.2.2. Market size analysis, y-o-y growth analysis (%)
7.3. Hepatitis
7.4. Herpes Simplex Virus
7.5. Influenza
7.6. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel segment
8.1.2. Market attractiveness index, By Distribution Channel segment
8.2. Hospital Pharmacies
8.2.1. Introduction
8.2.2. Market size analysis, y-o-y growth analysis (%)
8.3. Retail Pharmacies
8.4. E-commerce
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key region-specific dynamics
9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Competitive scenario
10.2. Competitor strategy analysis
10.3. Comparative type portfolio analysis
10.4. Market positioning/share analysis
10.5. Mergers and acquisitions analysis
11. COMPANY PROFILES
11.1. F. Hoffmann-La Roche
11.1.1. Company Overview
11.1.2. Type Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Gilead Sciences
11.3. GlaxoSmithKline
11.4. Bristol-Myers Squibb
11.5. Johnson & Johnson
11.6. Merck & Co.
11.7. AbbVie Inc.
11.8. Abbott Laboratories
11.9. AstraZeneca plc.
11.10. Pfizer Inc.
11.11. Cipla Inc.(*LIST NOT EXHAUSTIVE)
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About Us and Method of Fixation
12.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market impacting factors
4.2. Drivers
4.2.1. Growing Prevalence of Target Diseases
4.2.2. Strong Pipeline for Antiviral Drugs
4.3. Restraints
4.3.1. High Cost of Deployment
4.3.2. High Cost of Antiviral Drug Treatment
4.4. Opportunity
4.5. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Patent analysis
6. BY MECHANISM OF ACTION
6.1. Introduction
6.1.1. Market size analysis, and y-o-y growth analysis (%), By Mechanism of Action segment
6.1.2. Market attractiveness index, By Mechanism of Action segment
6.2. Nucleotide Polymerase Inhibitors
6.2.1. Introduction
6.2.2. Market size analysis, and y-o-y growth analysis (%)
6.3. Reverse Transcriptase Inhibitors
6.4. Protease Inhibitors
6.5. Others
7. BY APPLICATION
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%), By Application segment
7.1.2. Market attractiveness index, By Application segment
7.2. HIV
7.2.1. Introduction
7.2.2. Market size analysis, y-o-y growth analysis (%)
7.3. Hepatitis
7.4. Herpes Simplex Virus
7.5. Influenza
7.6. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel segment
8.1.2. Market attractiveness index, By Distribution Channel segment
8.2. Hospital Pharmacies
8.2.1. Introduction
8.2.2. Market size analysis, y-o-y growth analysis (%)
8.3. Retail Pharmacies
8.4. E-commerce
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key region-specific dynamics
9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action
9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Competitive scenario
10.2. Competitor strategy analysis
10.3. Comparative type portfolio analysis
10.4. Market positioning/share analysis
10.5. Mergers and acquisitions analysis
11. COMPANY PROFILES
11.1. F. Hoffmann-La Roche
11.1.1. Company Overview
11.1.2. Type Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Gilead Sciences
11.3. GlaxoSmithKline
11.4. Bristol-Myers Squibb
11.5. Johnson & Johnson
11.6. Merck & Co.
11.7. AbbVie Inc.
11.8. Abbott Laboratories
11.9. AstraZeneca plc.
11.10. Pfizer Inc.
11.11. Cipla Inc.(*LIST NOT EXHAUSTIVE)
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About Us and Method of Fixation
12.3. Contact Us
